compar
clinic
characterist
antibiot
therapi
communityacquir
pneumonia
patient
posit
respiratori
viru
molecular
test
polymeras
chain
reaction
neg
found
respiratori
viru
molecular
polymeras
chain
reaction
test
minim
impact
reduc
antibiot
util
among
viral
pneumonia
patient
compar
clinic
characterist
antibiot
therapi
communityacquir
pneumonia
patient
posit
respiratori
viru
molecular
test
polymeras
chain
reaction
neg
found
respiratori
viru
molecular
polymeras
chain
reaction
test
minim
impact
reduc
antibiot
util
among
viral
pneumonia
patient
associ
profession
infect
control
epidemiolog
inc
publish
elsevi
inc
right
reserv
communityacquir
pneumonia
cap
import
caus
morbid
mortal
unit
state
specif
microbiolog
etiolog
cap
frequent
difficult
identifi
recent
studi
suggest
viral
pathogen
account
approxim
total
case
inabl
differenti
bacteri
viral
etiolog
cap
base
clinic
present
physic
find
radiograph
find
routin
microbiolog
cultur
make
select
therapi
difficult
typic
case
treat
empir
bacteri
process
develop
molecular
diagnost
techniqu
may
help
allevi
situat
multiplex
polymeras
chain
reaction
pcr
technolog
recent
introduc
clinic
laboratori
may
facilit
identif
panel
potenti
respiratori
pathogen
respons
caus
cap
respiratori
viral
panel
rvp
pcrbase
technolog
detect
multipl
viral
pathogen
sensit
specif
diagnost
tool
offer
potenti
allow
physician
make
specif
diagnosi
viral
pneumonia
howev
remain
unclear
whether
improv
diagnost
accuraci
lead
reduct
unnecessari
antibiot
util
hospit
cap
patient
sever
studi
found
viral
pcr
test
reduc
antibiot
util
inpati
set
import
evalu
use
antibiot
therapi
inpati
viral
pneumonia
unnecessari
antibiot
therapi
may
foster
develop
multidrugresist
organ
increas
risk
clostridium
difficil
coliti
effort
address
issu
perform
analysi
antibiot
use
among
rvp
pcrposit
versu
neg
inpati
diagnos
cap
determin
whether
use
new
technolog
impact
reduc
antibiot
util
patient
viral
pneumonia
addit
evalu
clinic
characterist
outcom
cap
group
patient
multisit
cohort
studi
includ
hospit
adult
patient
diagnos
cap
test
use
pcrbase
rvp
calendar
year
patient
underw
rvp
test
hour
admiss
exclud
studi
manual
chart
review
also
done
identifi
patient
pneumonia
defin
clinic
sign
pneumonia
associ
lung
imag
demonstr
infiltr
without
cultur
growth
pcrrvp
test
perform
use
film
array
respiratori
panel
test
biofir
diagnost
llc
salt
lake
citi
ut
respiratori
virus
test
panel
pcr
adenoviru
coronaviru
metapneumoviru
rhinoviru
enteroviru
influenza
influenza
b
parainfluenza
respiratori
syncyti
viru
studi
protocol
review
approv
trihealth
institut
review
board
data
extract
trihealth
electron
medic
record
system
epic
system
verona
wi
main
outcom
util
antibiot
therapi
pneumonia
diagnosi
studi
outcom
includ
length
stay
intens
care
unit
day
mortal
ventil
day
discharg
disposit
data
demograph
comorbid
test
result
vital
laboratori
imag
result
collect
treatment
manag
evalu
determin
discontinu
antibiot
therapi
within
hour
pneumonia
diagnosi
univari
analysi
conduct
compar
outcom
studi
variabl
patient
rvp
posit
versu
rvp
neg
logist
regress
use
examin
adjust
risk
group
signific
variabl
test
fisher
exact
test
appropri
use
categor
variabl
continu
variabl
student
test
comparison
median
use
normal
nonnorm
distribut
data
respect
signific
level
analysi
statist
analysi
perform
use
spss
window
version
spss
inc
chicago
il
among
studi
subject
rvp
posit
viral
pathogen
rvp
neg
univari
analysi
reveal
age
year
leukocytosi
significantli
associ
neg
rvp
pcr
p
p
respect
addit
higher
white
blood
cell
count
creatinin
valu
admiss
significantli
associ
rvp
pcr
neg
p
p
respect
suggest
bacteri
etiolog
pneumonia
tabl
clinic
outcom
similar
rvpposit
rvpneg
group
among
patient
rvp
posit
continu
antibiot
treatment
day
diagnosi
pneumonia
versu
rvp
neg
p
tabl
found
patient
posit
rvp
result
less
like
treat
hour
antibiot
therapi
versu
patient
neg
rvp
result
howev
signific
differ
median
total
durat
antibiot
therapi
group
patient
consist
previou
studi
studi
suggest
physician
hesit
discontinu
antibiot
therapi
even
patient
found
viral
pneumonia
use
highli
sensit
specif
pcr
methodolog
clinic
challeng
syndrom
viral
pneumonia
issu
coinfect
bacteri
pathogen
report
occur
case
decis
continu
antibiot
therapi
despit
microbiolog
evid
viral
etiolog
depend
multipl
clinic
factor
includ
sever
ill
radiograph
imag
result
laboratori
studi
includ
white
blood
cell
count
comorbid
studi
reveal
leukocytosi
age
year
significantli
associ
rvp
pcrneg
case
suggest
applic
addit
clinic
laboratori
marker
combin
rvp
pcr
test
may
assist
physician
identifi
patient
may
appropri
discontinu
antibiot
procalcitonin
pct
biomark
found
valuabl
differenti
bacteri
viral
pneumonia
clinic
set
low
serum
pct
level
argu
bacteri
etiolog
cap
combin
result
rvp
pcr
test
pct
test
may
reassur
physician
patient
viral
pneumonia
bacteri
superinfect
turn
result
decreas
antibiot
overutil
studi
evalu
use
antibiot
therapi
cap
patient
rvp
pcr
pct
test
use
would
benefici
found
rvp
pcr
test
cap
patient
minim
impact
antibiot
util
addit
intervent
necessari
significantli
reduc
antibiot
overutil
viral
pneumonia
